Focused on developing innovative therapies for infectious diseases and cancer, this biotechnology company leverages its proprietary platform to advance novel treatments. Investors monitor its progress due to its pipeline targeting high unmet medical needs and potential for partnerships or acquisitions.
1 member of Congress has disclosed 2 trades in Enochian Biosciences, Inc. (ENOB), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-11-08 | Christopher L. Jacobs | sell | $1K – $15K |
| 2022-07-18 | Christopher L. Jacobs | buy | $1K – $15K |